Management of children with high-risk Hodgkin lymphoma

British Journal of Haematology

Volumn 157, Issue 1, 2012, Pages 3-13

  Kelly, Kara M ^a  

^a Department of Medicine   (United States)

Author keywords

Advanced stage; High risk; Hodgkin lymphoma; Paediatric; Unfavourable

Indexed keywords

BLEOMYCIN; BRENTUXIMAB VEDOTIN; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; EVEROLIMUS; FLUORODEOXYGLUCOSE F 18; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IFOSFAMIDE; LENALIDOMIDE; METHOTREXATE; METHYLPREDNISOLONE; NAVELBINE; PANOBINOSTAT; PREDNISONE; PROCARBAZINE; RAZOXANE; VINBLASTINE; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; AZOOSPERMIA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CHILD; CHILDHOOD CANCER; COMPUTER ASSISTED TOMOGRAPHY; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; EARLY MENOPAUSE; EVENT FREE SURVIVAL; FATIGUE; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HODGKIN DISEASE; HUMAN; INFECTION; LEUKEMIA; MARKER GENE; METASTASIS; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NAUSEA; NEUTROPENIA; OVARY INSUFFICIENCY; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; REED STERNBERG CELL; REVIEW; SALVAGE THERAPY; THROMBOCYTOPENIA; TREATMENT FAILURE;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; FEMALE; HODGKIN DISEASE; HUMANS; INFANT; MALE; PROGNOSIS; REMISSION INDUCTION; RISK FACTORS;

EID: 84858287763     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2011.08975.x     Document Type: Review

References (59)

1. Aldinucci, D., Lorenzon, D., Cattaruzza, L., Pinto, A., Gloghini, A., Carbone, A. & Colombatti, A. (2008) Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions. International Journal of Cancer, 122, 769-776.
2. Arya, L.S., Dinand, V., Thavaraj, V., Bakhshi, S., Dawar, R., Rath, G.K., Singh, R. & Vats, T.S. (2006) Hodgkin's disease in Indian children: outcome with chemotherapy alone. Pediatric Blood and Cancer, 46, 26-34.
3. Bauer, K., Skoetz, N., Monsef, I., Engert, A. & Brillant, C. (2011) Comparison of chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for patients with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database of Systematic Reviews, 8, CD007941.
4. Berg, S.L., Cairo, M.S., Russell, H., Ayello, J., Ingle, A.M., Lau, H., Chen, N., Adamson, P.C. & Blaney, S.M. (2011) Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report. Journal of Clinical Oncology, 29, 316-323.
5. Borchmann, P. & Diehl, V. (2011) Treatment of advanced stage Hodgkin lymphoma. In: Hodgkin Lymphoma: A Comprehensive Update on Diagnostics and Clinics (eds by A. Engert & S.J. Horning), pp. 191-202. Springer, Berlin Heidelberg.
6. Castellino, S.M., Geiger, A.M., Mertens, A.C., Leisenring, W.M., Tooze, J.A., Goodman, P., Stovall, M., Robison, L.L. & Hudson, M.M. (2011) Morbidity and mortality in long-term survivors of Hodgkin lymphoma: a report from the Childhood Cancer Survivor Study. Blood, 117, 1806-1816.
7. Chen, R., Gopal, A.K., Smith, S.E., Ansell, S.M., Rosenblatt, J.D., Klasa, R., Connors, J.M., Engert, A., Larsen, E.K., Kennedy, D.A., Sievers, E.L. & Younes, A. (2010) Results of a pivotal phase 2 study of brentuximab vedotin (SGN-35) in patients with relapsed or refractory Hodgkin lymphoma. Blood (ASH Annual Meeting Abstracts), 116, abstract, 283.
8. Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M. & Diehl, V. (2007) International Harmonization Project on lymphoma: revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579-586.
9. Claviez, A., Canals, C., Dierickx, D., Stein, J., Badell, I., Pession, A., Mackinnon, S., Slavin, S., Dalle, J.-H., Chacon, M.J., Sarhan, M., Wynne, R.F., Suttorp, M., Dini, G., Sureda, A. & Schmitz, N. (2009) Allogeneic hematopoietic stem cell transplantation in children and adolescents with recurrent and refractory Hodgkin lymphoma: an analysis of the European Group for Blood and Marrow Transplantation. Blood, 114, 2060-2067.
10. Dann, E.J., Bar-Shalom, R., Tamir, A., Haim, N., Ben-Shachar, M., Avivi, I., Zuckerman, T., Kirschbaum, M., Goor, O., Libster, D., Rowe, J.M. & Epelbaum, R. (2007) Risk-adapted BEACOPP regimen can reduce the cumulative dose of chemotherapy for standard and high-risk Hodgkin lymphoma with no impairment of outcome. Blood, 109, 905-909.
11. Diehl, V., Franklin, J., Pfreundschuh, M., Lathan, B., Paulus, U., Hasenclever, D., Tesch, H., Herrmann, R., Dörken, B., Müller-Hermelink, H.K., Dühmke, E. & Loeffler, M. (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. New England Journal of Medicine, 348, 2386-2395.
12. Dörffel, W., Lüders, H., Rühl, U., Albrecht, M., Marciniak, H., Parwaresch, R., Pötter, R., Schellong, G., Schwarze, E.W. & Wickmann, L. (2003) Preliminary results of the multicenter trial GPOH-HD 95 for the treatment of Hodgkin's disease in children and adolescents: analysis and outlook. Klinische Padiatrie, 215, 139-145.
13. Emmerich, F., Meiser, M., Hummel, M., Demel, G., Foss, H.D., Jundt, F., Mathas, S., Krappmann, D., Scheidereit, C., Stein, H. & Dörken, B. (1999) Overexpression of I Kappa B alpha without inhibition of NF-kappaB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood, 94, 3129-3134.
14. Engert, A., Diehl, V., Franklin, J., Lohri, A., Dörken, B., Ludwig, W.D., Koch, P., Hänel, M., Pfreundschuh, M., Wilhelm, M., Trümper, L., Aulitzky, W.E., Bentz, M., Rummel, M., Sezer, O., Müller-Hermelink, H.K., Hasenclever, D. & Löffler, M. (2009) Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10years of follow-up of the GHSG HD9 study. Journal of Clinical Oncology, 27, 4548-4554.
15. Fanale, M.A., Forero-Torres, A., Rosenblatt, J.D., Advani, R.H., Franklin, A.R., Kennedy, D.A., Han, T.H., Sievers, E.L. & Bartlett, N.L. (2011) A phase 1 weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clinical Cancer Research. [Epub ahead of print] doi:.
16. Federico, M., Bellei, M., Brice, P., Brugiatelli, M., Nagler, A., Gisselbrecht, C., Moretti, L., Colombat, P., Luminari, S., Fabbiano, F., Di Renzo, N., Goldstone, A. & Carella, A.M. (2003) EBMT/GISL/ANZLG/SFGM/GELA Intergroup HD01 Trial. High-dose therapy and autologous stem-cell transplantation versus conventional therapy for patients with advanced Hodgkin's lymphoma responding to front-line therapy. Journal of Clinical Oncology, 21, 2320-2325.
17. Federico, M., Luminari, S., Iannitto, E., Polimeno, G., Marcheselli, L., Montanini, A., La Sala, A., Merli, F., Stelitano, C., Pozzi, S., Scalone, R., Di Renzo, N., Musto, P., Baldini, L., Cervetti, G., Angrilli, F., Mazza, P., Brugiatelli, M. & Gobbi, P.G. (2009) ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. Journal of Clinical Oncology, 27, 805-811.
18. Fehniger, T.A., Larson, S., Trinkaus, K., Siegel, M.J., Cashen, A.F., Blum, K.A., Fenske, T.S., Hurd, D.P., Goy, A., Schneider, S.E., Keppel, C.R., Wagner-Johnston, N.D., Carson, K.R. & Bartlett, N.L. (2011) A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. Blood, 118, 5119-5125.
19. Fiore, F., Patti, K., Viviani, S., Rossi, A., Di Raimondo, F., Cantonetti, M., Feldman, T., Biggi, A., Barrington, S. & Gallamini, A. (2010) Effect of early chemotherapy intensification with BEACOPP in high-risk, interim-PET positive, advanced-stage Hodgkin lymphoma on overall treatment outcome of ABVD. Journal of Clinical Oncology, 28, abstract, 8006.
20. Fouladi, M., Laningham, F., Wu, J., O'Shaughnessy, M.A., Molina, K., Broniscer, A., Spunt, S.L., Luckett, I., Stewart, C.F., Houghton, P.J., Gilbertson, R.J. & Furman, W.L. (2007) Phase I study of everolimus in pediatric patients with refractory solid tumors. Journal of Clinical Oncology, 25, 4806-4812.
21. Friedman, D.l., Wolden, S., Constine, L., Chen, L., McCarten, K.M., Fitzgerald, T.J., De Alarcon, P.D., Chen, A.R., Hutchison, R., Ehrlich, P., Kobrinsky, N.L., Higman, M., Hogan S., Roll.L., Trippett, T. & Schwartz, C. (2010) AHOD0031: a phase III study of dose-intensive therapy for intermediate risk Hodgkin lymphoma: a report from the Children's Oncology Group. Blood, 116, abstract, 766.
22. Gallamini, A., Hutchings, M., Rigacci, L., Specht, L., Merli, F., Hansen, M., Patti, C., Loft, A., Di Raimondo, F., D'Amore, F., Biggi, A., Vitolo, U., Stelitano, C., Sancetta, R., Trentin, L., Luminari, S., Iannitto, E., Viviani, S., Pierri, I. & Levis, A. (2007) Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. Journal of Clinical Oncology, 25, 3746-3752.
23. Gobbi, P.G., Levis, A., Chisesi, T., Broglia, C., Vitolo, U., Stelitano, C., Pavone, V., Cavanna, L., Santini, G., Merli, F., Liberati, M., Baldini, L., Deliliers, G.L., Angelucci, E., Bordonaro, R. & Federico, M. (2005) ABVD versus modified Stanford V versus MOPPEBVCAD with optional and limited radiotherapy in intermediate- and advanced-stage Hodgkin's lymphoma: rinal results of a multicenter randomized trial by the Intergruppo Italiano Linfomi. Journal of Clinical Oncology, 23, 9198-9207.
24. Gordon, L.I., Hong, F., Fisher, R.I., Bartlett, N.L., Connors, J.M., Gascoyne, R.D., Wagner, H., Stiff, P.J., Cheson, B.D., Gospodarowicz, M., Advani, R., Brad Kahl, B., Friedberg, J.W., Blum, K.A., Habermann, T.M., Tuscano, J., Hoppe, R. & Horning, S.J. (2010) A randomized phase III trial of ABVDVs. StanfordV +/- radiation therapy in locally extensive and advanced stage Hodgkin's lymphoma: an Intergroup Study Coordinated by the Eastern Cooperatve Oncology Group (E2496). Blood (ASH Annual Meeting Abstracts), 116, abstract, 415.
25. Hakvoort-Cammel, F.G., Buitendijk, S., van den Heuvel-Eibrink, M. & Hählen, K. (2004) Treatment of pediatric Hodgkin disease avoiding radiotherapy: excellent outcome with the Rotterdam-HD-84-Protocol. Pediatric Blood and Cancer, 43, 8-16.
26. Hasenclever, D. & Diehl, V. (1998) A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. New England Journal of Medicine, 339, 1506-1514.
27. Horton, T.M., Sheehan, A., Dolores Lopez-Terrada, D., Hutchison, R., Narendra, S., Wu, M.-F., Chen, L. & Liu, H. (2010) Coordinate regulation of NF-κB subunit expression in pediatric Hodgkin lymphoma patients with rapid early response to therapy, but not slow early response to therapy. Blood (ASH Annual Meeting Abstracts), 116, abstract, 2680.
28. Hoskin, P.J., Lowry, L., Horwich, A., Jack, A., Mead, B., Hancock, B.W., Smith, P., Qian, W., Patrick, P., Popova, B., Pettitt, A., Cunningham, D., Pettengell, R., Sweetenham, J., Linch, D. & Johnson, P.W. (2009) Randomized comparison of the Stanford V regimen and ABVD in the treatment of advanced Hodgkin's lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244. Journal of Clinical Oncology, 27, 5390-5396.
29. Hudson, M.M., Krasin, M., Link, M.P., Donaldson, S.S., Billups, C., Merchant, T.E., Kun, L., Billet, A.L., Kaste, S., Tarbell, N.J., Howard, S., Friedmann, A.M., Hurwitz, C.A., Young, J.A., Marcus, K.C., Rai, S., Cowan, T. & Weinstein, H.J. (2004) Risk-adapted, combined-modality therapy with VAMP/COP and response-based, involved-field radiation for unfavorable pediatric Hodgkin's disease. Journal of Clinical Oncology, 22, 4541-4550.
30. Johnston, L.J. & Horning, S.J. (2000) Autologous hematopoietic cell transplantation in Hodgkin's disease. Biology of Blood and Marrow Transplantation, 6, 289-300.
31. Johnston, P.B., Inwards, D.J., Colgan, J.P., Laplant, B.R., Kabat, B.F., Habermann, T.M., Micallef, I.N., Porrata, L.F., Ansell, S.M., Reeder, C.B., Roy, V. & Witzig, T.E. (2010) A phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma. American Journal of Hematology, 85, 320-324.
32. Josting, A., Rudolph, C., Mapara, M., Glossmann, J.P., Sieniawski, M., Sieber, M., Kirchner, H.H., Dörken, B., Hossfeld, D.K., Kisro, J., Metzner, B., Berdel, W.E., Diehl, V. & Engert, A. (2005) Cologne high-dose sequential chemotherapy in relapsed and refractory Hodgkin lymphoma: results of a large multicenter study of the German Hodgkin Lymphoma Study Group (GHSG). Annals of Oncology, 16, 116-123.
33. Keller, F.G., Nachman, J., Constine, L., Thomson, J., McCarten, K.M., Chen, L. & Schwartz, C. (2010) A phase III study for the treatment of children and adolescents with newly diagnosed low risk Hodgkin lymphoma (HL). Blood (ASH Annual Meeting Abstracts), 116, abstract, 767.
34. Kelly, K.M., Sposto, R., Hutchinson, R., Massey, V., McCarten, K., Perkins, S., Lones, M., Villaluna, D. & Weiner, M. (2011) BEACOPP chemotherapy is a highly effective regimen in children and adolescents with high risk Hodgkin lymphoma: a report from the Children's Oncology Group. Blood, 117, 2596-2603.
35. Khan, G. (2006) Epstein-Barr virus, cytokines, and inflammation: a cocktail for the pathogenesis of Hodgkin's lymphoma? Experimental Hematology, 34, 399-406.
36. Koh, E.S., Tran, T.H., Heydarian, M., Sachs, R.K., Tsang, R.W., Brenner, D.J., Pintilie, M., Xu, T., Chung, J., Paul, N. & Hodgson, D.C. (2007) A comparison of mantle versus involved-field radiotherapy for Hodgkin's lymphoma: reduction in normal tissue dose and second cancer risk. Radiation Oncology, 15, 2-13.
37. Kuppers, R. (2009) The biology of Hodgkin's lymphoma. Nature Reviews Cancer, 9, 15-27.
38. Laskar, S., Gupta, T., Vima, S., Muckaden, M.A., Saikia, T.K., Pai, S.K., Naresh, K.N. & Dinshaw, K.A. (2004) Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? Journal of Clinical Oncology, 22, 62-68.
39. Levine, J., Canada, A. & Stern, C.J. (2010) Fertility preservation in adolescents and young adults with cancer. Journal of Clinical Oncology, 28, 4831-4841.
40. Mauz-Körholz, C., Hasenclever, D., Dörffel, W., Ruschke, K., Pelz, T., Voigt, A., Stiefel, M., Winkler, M., Vilser, C., Dieckmann, K., Karlén, J., Bergsträsser, E., Fosså, A., Mann, G., Hummel, M., Klapper, W., Stein, H., Vordermark, D., Kluge, R. & Körholz, D. (2010) Procarbazine-free OEPA-COPDAC chemotherapy in boys and standard OPPA-COPP in girls have comparable effectiveness in pediatric Hodgkin's lymphoma: the GPOH-HD-2002 study. Journal of Clinical Oncology, 28, 3680-3686.
41. Myrehaug, S., Pintilie, M., Yun, L., Crump, M., Tsang, R.W., Meyer, R.M., Sussman, J., Yu, E. & Hodgson, D.C. (2010) A population-based study of cardiac morbidity among Hodgkin lymphoma patients with preexisting heart disease. Blood, 116, 2237-2240.
42. Nachman, J.B., Sposto, R., Herzog, P., Gilchrist, G.S., Wolden, S.L., Thomson, J., Kadin, M.E., Pattengale, P., Davis, P.C., Hutchinson, R.J. & White, W. (2002) Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. Journal of Clinical Oncology, 20, 3765-3771.
43. Niens, M., Visser, L., Nolte, I.M., Van Der Steege, G., Diepstra, A., Cordano, P., Jarrett, R.F., Te Meerman, G.J., Poppema, S. & van den Berg, A. (2008) Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22. British Journal of Haematology, 140, 527-536.
44. O'Brien, M.M., Donaldson, S.S., Balise, R.R., Whittemore, A.S. & Link, M.P. (2010) Second malignant neoplasms in survivors of pediatric Hodgkin's lymphoma treated with low-dose radiation and chemotherapy. Journal of Clinical Oncology, 28, 1232-1239.
45. Plattel, W., Van Den Berg, A., Van der Graaf, A.M., Vos, H., Visser, L., Diepstra, A. & van Imhoff, G. (2010) Mid-treatment plasma levels of thymus activated and regulated chemokine (TARC) predict treatment outcome in classical Hodgkin lymphoma patients. Blood (ASH Annual Meeting Abstracts), 116, abstract, 748.
46. Qi, L., Cazares, L., Johnson, C., de Alarcon, P., Kupfer, G.M. & Semmes, O.J. (2008) Serum protein expression profiling in pediatric Hodgkin lymphoma: a report from the Children's Oncology Group. Pediatric Blood and Cancer, 51, 216-221.
47. Schellong, G., Pötter, R., Brämswig, J., Wagner, W., Prott, F.J., Dörffel, W., Körholz, D., Mann, G., Rath, B., Reiter, A., Weissbach, G., Riepenhausen, M., Thiemann, M. & Schwarze, E.W. (1999) High cure rates and reduced long-term toxicity in pediatric Hodgkin's disease: the German-Austrian Multicenter Trial DAL-HD-90. The German-Austrian Pediatric Hodgkin's Disease Study Group. Journal of Clinical Oncology, 17, 3736-3744.
48. Schwartz, C.L., Constine, L.S., Villaluna, D., London, W.B., Hutchison, R.E., Sposto, R., Lipshultz, S.E., Turner, C.S., deAlarcon, P.A. & Chauvenet, A. (2009) A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425. Blood, 114, 2051-2059.
49. Schwartz, C.L., Friedman, D.L., McCarten, K., Wolden, S.L., Voss, S., Constine, L.S. & Chen, L. (2011) Predictors of early response and event-free survival in Hodgkin lymphoma (HL): PET versus CT imaging. Journal of Clinical Oncology, 29(Suppl.), abstract, 8006.
50. Skinnider, B.F. & Mak, T.W. (2002) The role of cytokines in classical Hodgkin lymphoma. Blood, 99, 4283-4297.
51. Smith, R.S., Chen, Q., Hudson, M.M., Link, M.P., Kun, L., Weinstein, H., Billett, A., Marcus, K.J., Tarbell, N.J. & Donaldson, S.S. (2003) Prognostic factors for children with Hodgkin's disease treated with combined-modality therapy. Journal of Clinical Oncology, 21, 2026-2033.
52. Steidl, C., Lee, T., Shah, S.P., Farinha, P., Han, G., Nayar, T., Delaney, A., Jones, S.J., Iqbal, J., Weisenburger, D.D., Bast, M.A., Rosenwald, A., Muller-Hermelink, H.K., Rimsza, L.M., Campo, E., Delabie, J., Braziel, R.M., Cook, J.R., Tubbs, R.R., Jaffe, E.S., Lenz, G., Connors, J.M., Staudt, L.M., Chan, W.C. & Gascoyne, R.D. (2010) Tumor-associated macrophages and survival in classic Hodgkin's lymphoma. New England Journal of Medicine, 362, 875-885.
53. Steidl, C., Connors, J.M. & Gascoyne, R.D. (2011) Molecular pathogenesis of Hodgkin's lymphoma: increasing evidence of the importance of the microenvironment. Journal of Clinical Oncology, 29, 1812-1826.
54. Sureda, A., Younes, A., Ben-Yehuda, D., Ong, T.-C., Kaufman, J.L., Le Corre, C., Gallagher, J., Shen, A. & Engert, A. (2010) Final analysis: Phase II study of oral panobinostat in relapsed/refractory Hodgkin lymphoma patients following autologous hematopoietic Stem Cell Transplant. Blood (ASH Annual Meeting Abstracts), 116, abstract, 419.
55. Tebbi, C.K., London, W.B., Friedman, D., Villaluna, D., De Alarcon, P.A., Constine, L.S., Mendenhall, N.P., Sposto, R., Chauvenet, A. & Schwartz, C.L. (2007) Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. Journal of Clinical Oncology, 25, 493-500.
56. Teruya-Feldstein, J., Tosato, G. & Jaffe, E.S. (2000) The role of chemokines in Hodgkin's disease. Leukemia Lymphoma, 38, 363-371.
57. Viviani, S., Zinzani, P.L., Rambaldi, A., Brusamolino, E., Levis, A., Bonfante, V., Vitolo, U., Pulsoni, A., Liberati, A.M., Specchia, G., Valagussa, P., Rossi, A., Zaja, F., Pogliani, E.M., Pregno, P., Gotti, M., Gallamini, A., Rota Scalabrini, D., Bonadonna, G. & Gianni, A.M. (2011) ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. New England Journal of Medicine, 365, 203-212.
58. Weihrauch, M.R., Manzke, O., Beyer, M., Haverkamp, H., Diehl, V., Bohlen, H., Wolf, J. & Schultze, J.L. (2005) Elevated serum levels of CC thymus and activation-related chemokine (TARC) in primary Hodgkin's disease: potential for a prognostic factor. Cancer Research, 65, 5516-5519.
59. Weiner, M.A., Leventhal, B., Brecher, M.L., Marcus, R.B., Cantor, A., Gieser, P.W., Ternberg, J.L., Behm, F.G., Wharam, M.D., Jr & Chauvenet, A.R. (1997) Randomized study of intensive MOPP-ABVD with or without low-dose total-nodal radiation therapy in the treatment of stages IIB, IIIA2, IIIB, and IV Hodgkin's disease in pediatric patients. A Pediatric Oncology Group study. Journal of Clinical Oncology, 15, 2769-2779.